UK’s drug payment disclosure system fails to protect patients and public trust

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.)  It’s of­fi­cial: Gen­er­al Cat­a­lyst is about to

Ar­row­head Phar­ma­ceu­ti­cals’ RNAi treat­ment has suc­ceed­ed in a reg­is­tra­tional test in pa­tients with an ul­tra-rare lipid me­tab­o­lism dis­or­der, bol­ster­ing plans for a reg­u­la­to­ry fil­ing that